Belite Bio (BLTE) CEO Lin Yu-Hsin details option and share holdings

Rhea-AI Filing Summary

Belite Bio, Inc. director and CEO Lin Yu-Hsin has reported initial equity holdings, including stock options and share positions. The filing lists multiple stock options over ordinary shares with exercise prices from $0.4386 to $158.3600, expiring between 2030 and 2036. Several options are already fully vested, while others vest monthly through August 2028 and in annual tranches on January 9, 2027, January 9, 2028, and January 9, 2029. Lin also holds American depositary shares and ordinary shares directly. This Form 3 records existing positions; it does not show new buying or selling activity.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lin Yu-Hsin

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American depositary share(1)	180,134	D
Ordinary Share	172,949	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	12/22/2030	Ordinary Shares	206,954	$0.4386	D
Stock Option (right to buy)	(3)	04/17/2032	Ordinary Shares	27,778	$6	D
Stock Option (right to buy)	(4)	07/16/2033	Ordinary Shares	166,667	$14.45	D
Stock Option (right to buy)	(5)	08/28/2034	Ordinary Shares	208,334	$48.46	D
Stock Option (right to buy)	(6)	02/11/2035	Ordinary Shares	200,000	$54.88	D
Stock Option (right to buy)	(7)	10/06/2035	Ordinary Shares	40,000	$77.4	D
Stock Option (right to buy)	(8)	10/27/2035	Ordinary Shares	80,000	$93.02	D
Stock Option (right to buy)	(9)	01/08/2036	Ordinary Shares	150,000	$158.36	D

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer.

2. The option to purchase 206,954 ordinary shares had vested prior to March 18, 2026.

3. The option to purchase 27,778 ordinary shares had vested prior to March 18, 2026.

4. The option to purchase 145,833 ordinary shares had vested prior to March 18, 2026. The option shall vest as to the remaining 20,834 ordinary shares in five equal and continuous monthly installments at the end of each month from March 2026 to July 2026, subject to continued service to the Issuer on each such date.

5. The option to purchase 83,334 ordinary shares had vested prior to March 18, 2026. The option shall vest as to the remaining 125,000 ordinary shares in 18 monthly equal and continuous installments at the end of each month from March 2026 to August 2028, subject to continued service to the Issuer on each such date.

6. The option shall vest as to 200,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following February 12, 2025, subject to continued service to the Issuer on each such date.

7. The option to purchase 40,000 ordinary shares had vested prior to March 18, 2026.

8. The option to purchase 80,000 ordinary shares had vested prior to March 18, 2026.

9. The option shall vest (i) as to 50,000 ordinary shares on January 9, 2027, (ii) as to 50,000 ordinary shares on January 9, 2028, and (iii) as to 50,000 ordinary shares on January 9, 2029.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Yu-Hsin Lin	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Lin Yu-Hsin report owning in Belite Bio (BLTE) on this Form 3?

Lin Yu-Hsin reports direct holdings of stock options, American depositary shares, and ordinary shares of Belite Bio. The options cover ordinary shares at various exercise prices and expiration dates, with some already vested and others scheduled to vest over several years.

Are there any buy or sell transactions in this Belite Bio (BLTE) Form 3?

No buy or sell transactions are shown; the entries are reported as holdings. The summary data indicates zero buy, sell, acquire, or dispose counts, with all ten entries classified as holding records and an overall neutral net buy/sell direction.

What are the key stock option terms reported for Belite Bio (BLTE) CEO Lin Yu-Hsin?

The Form 3 lists several stock options to buy ordinary shares with exercise prices from $0.4386 up to $158.3600, expiring between 2030-12-22 and 2036-01-08. Footnotes describe detailed vesting schedules, including monthly and annual vesting milestones.

How do the Belite Bio (BLTE) stock options for Lin Yu-Hsin vest over time?

Some options were fully vested before March 18, 2026, while others vest in equal monthly installments through July 2026 and August 2028. Another grant vests in three tranches on January 9, 2027, January 9, 2028, and January 9, 2029.

What does the Belite Bio (BLTE) Form 3 show about Lin Yu-Hsin’s derivative positions?

The derivative summary lists multiple stock option positions over ordinary shares, each with a specific exercise price and expiration date. These options represent unexercised rights to acquire shares in the future and remain outstanding as direct holdings according to the filing.

How are American depositary shares treated in this Belite Bio (BLTE) Form 3?

The filing notes that each American depositary share represents one ordinary share with a par value of $0.0001. Lin Yu-Hsin holds a direct position in these depositary shares in addition to directly held ordinary shares and stock options.